Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Low Back Pain | 12 | 2020 | 47 | 2.650 |
Why?
|
| Analgesics, Opioid | 14 | 2022 | 265 | 1.710 |
Why?
|
| Pain, Postoperative | 10 | 2019 | 205 | 1.610 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 69 | 1.520 |
Why?
|
| Autonomic Nerve Block | 3 | 2015 | 11 | 1.300 |
Why?
|
| Primary Health Care | 8 | 2025 | 240 | 1.170 |
Why?
|
| Pain Measurement | 18 | 2020 | 385 | 1.110 |
Why?
|
| Analgesics | 9 | 2018 | 117 | 1.000 |
Why?
|
| Health Policy | 2 | 2025 | 96 | 0.970 |
Why?
|
| Perioperative Care | 3 | 2019 | 57 | 0.950 |
Why?
|
| Electronic Health Records | 5 | 2025 | 184 | 0.890 |
Why?
|
| Medicaid | 1 | 2025 | 105 | 0.880 |
Why?
|
| Sacroiliac Joint | 3 | 2014 | 12 | 0.870 |
Why?
|
| Insurance Coverage | 1 | 2025 | 82 | 0.860 |
Why?
|
| Midazolam | 2 | 2014 | 11 | 0.850 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2014 | 6 | 0.850 |
Why?
|
| Conscious Sedation | 2 | 2014 | 26 | 0.850 |
Why?
|
| Anesthetics, Intravenous | 2 | 2014 | 20 | 0.850 |
Why?
|
| Fentanyl | 2 | 2014 | 37 | 0.840 |
Why?
|
| Complex Regional Pain Syndromes | 2 | 2014 | 24 | 0.840 |
Why?
|
| Humans | 62 | 2025 | 34562 | 0.820 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 245 | 0.810 |
Why?
|
| Pain | 7 | 2012 | 330 | 0.780 |
Why?
|
| Obesity | 5 | 2014 | 1246 | 0.770 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2008 | 83 | 0.750 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2025 | 64 | 0.740 |
Why?
|
| Osteoarthritis, Knee | 1 | 2023 | 96 | 0.740 |
Why?
|
| Fear | 3 | 2014 | 46 | 0.600 |
Why?
|
| Buprenorphine | 1 | 2019 | 14 | 0.590 |
Why?
|
| Treatment Outcome | 15 | 2023 | 3623 | 0.570 |
Why?
|
| Male | 40 | 2025 | 20739 | 0.540 |
Why?
|
| Zygapophyseal Joint | 2 | 2007 | 3 | 0.540 |
Why?
|
| Resistance Training | 2 | 2014 | 84 | 0.500 |
Why?
|
| Anesthetics, Local | 3 | 2015 | 96 | 0.500 |
Why?
|
| Neuralgia | 2 | 2015 | 47 | 0.500 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2006 | 21 | 0.490 |
Why?
|
| Amines | 3 | 2006 | 24 | 0.490 |
Why?
|
| Denervation | 4 | 2008 | 13 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 431 | 0.470 |
Why?
|
| Middle Aged | 23 | 2025 | 12726 | 0.450 |
Why?
|
| Stellate Ganglion | 1 | 2015 | 1 | 0.450 |
Why?
|
| Ventricular Fibrillation | 1 | 2015 | 7 | 0.450 |
Why?
|
| Medulla Oblongata | 5 | 2007 | 51 | 0.450 |
Why?
|
| Disability Evaluation | 3 | 2014 | 262 | 0.440 |
Why?
|
| Receptors, Opioid, mu | 4 | 2007 | 36 | 0.430 |
Why?
|
| Phantom Limb | 1 | 2014 | 4 | 0.430 |
Why?
|
| Receptors, Opioid, delta | 5 | 2007 | 15 | 0.410 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 364 | 0.410 |
Why?
|
| Schools, Medical | 1 | 2014 | 46 | 0.400 |
Why?
|
| United States | 9 | 2025 | 4278 | 0.400 |
Why?
|
| Female | 29 | 2025 | 21531 | 0.400 |
Why?
|
| Exercise Therapy | 2 | 2014 | 283 | 0.390 |
Why?
|
| Anesthesiology | 1 | 2014 | 53 | 0.390 |
Why?
|
| Faculty, Medical | 1 | 2014 | 81 | 0.390 |
Why?
|
| Diabetic Neuropathies | 2 | 2013 | 29 | 0.380 |
Why?
|
| Spinal Cord | 4 | 2004 | 150 | 0.360 |
Why?
|
| Adult | 16 | 2025 | 10030 | 0.360 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 176 | 0.360 |
Why?
|
| Nociceptors | 6 | 2004 | 45 | 0.360 |
Why?
|
| Health Behavior | 1 | 2013 | 246 | 0.360 |
Why?
|
| Postoperative Care | 3 | 2019 | 80 | 0.350 |
Why?
|
| Osteoarthritis | 1 | 2012 | 80 | 0.350 |
Why?
|
| Walking | 4 | 2014 | 217 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 45 | 0.300 |
Why?
|
| Societies, Medical | 3 | 2018 | 168 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 565 | 0.290 |
Why?
|
| Catheter Ablation | 2 | 2008 | 116 | 0.290 |
Why?
|
| Pain Threshold | 2 | 2008 | 105 | 0.280 |
Why?
|
| Aged | 14 | 2018 | 11022 | 0.280 |
Why?
|
| Ketamine | 2 | 2018 | 20 | 0.280 |
Why?
|
| Hyperalgesia | 4 | 2007 | 86 | 0.280 |
Why?
|
| Inflammation | 4 | 2007 | 557 | 0.270 |
Why?
|
| Patient Selection | 2 | 2022 | 291 | 0.270 |
Why?
|
| Spinal Diseases | 1 | 2007 | 24 | 0.270 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 3 | 2007 | 18 | 0.270 |
Why?
|
| Risk Factors | 9 | 2019 | 4137 | 0.260 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 54 | 0.260 |
Why?
|
| Oligopeptides | 4 | 2007 | 55 | 0.250 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 101 | 0.250 |
Why?
|
| Ganglia, Spinal | 2 | 2006 | 72 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 67 | 0.240 |
Why?
|
| Analgesia | 2 | 2016 | 32 | 0.230 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 136 | 0.230 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 4157 | 0.230 |
Why?
|
| Illinois | 1 | 2025 | 11 | 0.230 |
Why?
|
| Texas | 1 | 2025 | 40 | 0.230 |
Why?
|
| Physical Endurance | 3 | 2013 | 42 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2007 | 923 | 0.220 |
Why?
|
| Nerve Block | 3 | 2012 | 63 | 0.210 |
Why?
|
| Gait | 3 | 2014 | 134 | 0.210 |
Why?
|
| Radiosurgery | 1 | 2007 | 361 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 152 | 0.210 |
Why?
|
| North Carolina | 2 | 2025 | 1613 | 0.210 |
Why?
|
| Enkephalins | 2 | 2001 | 11 | 0.210 |
Why?
|
| Brain | 3 | 2019 | 1031 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 201 | 0.200 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 183 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 237 | 0.200 |
Why?
|
| Efferent Pathways | 1 | 2003 | 11 | 0.190 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 14 | 0.190 |
Why?
|
| Naproxen | 1 | 2002 | 7 | 0.190 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 248 | 0.190 |
Why?
|
| Injections, Spinal | 3 | 2016 | 124 | 0.190 |
Why?
|
| Acetates | 1 | 2002 | 14 | 0.190 |
Why?
|
| Rats | 9 | 2007 | 1946 | 0.190 |
Why?
|
| Algorithms | 2 | 2017 | 561 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 304 | 0.190 |
Why?
|
| Research Design | 2 | 2017 | 337 | 0.190 |
Why?
|
| Muscle Strength | 2 | 2013 | 157 | 0.180 |
Why?
|
| Consensus | 5 | 2019 | 92 | 0.180 |
Why?
|
| Knee Joint | 1 | 2023 | 151 | 0.180 |
Why?
|
| Neurons | 2 | 2003 | 491 | 0.180 |
Why?
|
| Anesthesia, Conduction | 2 | 2018 | 27 | 0.170 |
Why?
|
| Hematology | 1 | 2020 | 9 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 939 | 0.160 |
Why?
|
| Animals | 12 | 2010 | 8578 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 948 | 0.160 |
Why?
|
| Body Mass Index | 3 | 2013 | 954 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2020 | 106 | 0.150 |
Why?
|
| Periaqueductal Gray | 1 | 2019 | 2 | 0.150 |
Why?
|
| User-Computer Interface | 1 | 2019 | 55 | 0.150 |
Why?
|
| Neoplasms | 1 | 2025 | 793 | 0.140 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 16 | 0.130 |
Why?
|
| Classification | 1 | 2017 | 1 | 0.130 |
Why?
|
| Analgesia, Epidural | 2 | 2010 | 55 | 0.130 |
Why?
|
| Microinjections | 4 | 2001 | 39 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2017 | 41 | 0.130 |
Why?
|
| Medical Informatics | 1 | 2016 | 27 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2016 | 128 | 0.120 |
Why?
|
| Lumbar Vertebrae | 2 | 2007 | 114 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 87 | 0.120 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 100 | 0.120 |
Why?
|
| Placebos | 1 | 2015 | 69 | 0.120 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 12 | 0.120 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 230 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 101 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 76 | 0.110 |
Why?
|
| Sympathectomy | 1 | 2015 | 24 | 0.110 |
Why?
|
| Volleyball | 1 | 2015 | 1 | 0.110 |
Why?
|
| Terminology as Topic | 3 | 2019 | 71 | 0.110 |
Why?
|
| Family Practice | 1 | 2015 | 49 | 0.110 |
Why?
|
| Electric Countershock | 1 | 2015 | 18 | 0.110 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2008 | 26 | 0.110 |
Why?
|
| Drug Synergism | 4 | 2007 | 69 | 0.110 |
Why?
|
| Young Adult | 3 | 2019 | 2831 | 0.110 |
Why?
|
| Soccer | 1 | 2015 | 19 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 306 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2015 | 3825 | 0.110 |
Why?
|
| Overweight | 2 | 2013 | 289 | 0.110 |
Why?
|
| Qualitative Research | 3 | 2020 | 199 | 0.110 |
Why?
|
| Spinal Nerves | 1 | 2015 | 72 | 0.110 |
Why?
|
| Brain Concussion | 1 | 2015 | 65 | 0.110 |
Why?
|
| Injections, Intra-Articular | 1 | 2014 | 16 | 0.100 |
Why?
|
| False Positive Reactions | 1 | 2014 | 30 | 0.100 |
Why?
|
| Efficiency | 1 | 2014 | 18 | 0.100 |
Why?
|
| Joints | 1 | 2013 | 12 | 0.100 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2013 | 6 | 0.100 |
Why?
|
| Baseball | 1 | 2015 | 48 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 261 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 18 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 177 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2013 | 74 | 0.100 |
Why?
|
| Affect | 1 | 2013 | 72 | 0.100 |
Why?
|
| Phobic Disorders | 1 | 2013 | 10 | 0.100 |
Why?
|
| Time Factors | 5 | 2019 | 2353 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2014 | 191 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2013 | 439 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 54 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2013 | 130 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 145 | 0.090 |
Why?
|
| Celiac Plexus | 1 | 2012 | 3 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2019 | 1508 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2014 | 380 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 590 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 1290 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2013 | 222 | 0.090 |
Why?
|
| Adolescent | 4 | 2019 | 3805 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 135 | 0.080 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 40 | 0.080 |
Why?
|
| Checklist | 1 | 2010 | 39 | 0.080 |
Why?
|
| Diet | 1 | 2012 | 418 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2019 | 44 | 0.070 |
Why?
|
| Epidural Space | 1 | 2009 | 9 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 575 | 0.070 |
Why?
|
| Steroids | 1 | 2009 | 39 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2013 | 310 | 0.070 |
Why?
|
| HIV Infections | 1 | 2013 | 429 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 110 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1393 | 0.070 |
Why?
|
| Neck Pain | 1 | 2007 | 6 | 0.070 |
Why?
|
| Radiculopathy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Hindlimb | 3 | 2007 | 55 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2008 | 193 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 46 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 176 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2008 | 182 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 153 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 123 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 136 | 0.060 |
Why?
|
| Nortriptyline | 1 | 2006 | 2 | 0.060 |
Why?
|
| Carbamazepine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Reaction Time | 2 | 2007 | 131 | 0.060 |
Why?
|
| Thoracotomy | 1 | 2006 | 24 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2006 | 44 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 755 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2006 | 62 | 0.060 |
Why?
|
| Mastectomy | 1 | 2006 | 64 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2003 | 36 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1034 | 0.060 |
Why?
|
| Urban Population | 1 | 2025 | 97 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1128 | 0.050 |
Why?
|
| Registries | 1 | 2025 | 328 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 79 | 0.050 |
Why?
|
| Calcium | 2 | 2002 | 343 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 926 | 0.050 |
Why?
|
| Rural Population | 1 | 2025 | 297 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 260 | 0.050 |
Why?
|
| Receptors, GABA | 1 | 2003 | 7 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 9 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2003 | 14 | 0.050 |
Why?
|
| Medicare | 1 | 2004 | 224 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 11 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 193 | 0.050 |
Why?
|
| Narcotics | 1 | 2003 | 32 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2003 | 90 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 1032 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Research Subjects | 1 | 2022 | 19 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 63 | 0.050 |
Why?
|
| Exercise Test | 2 | 2013 | 247 | 0.040 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2001 | 4 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 77 | 0.040 |
Why?
|
| Chemokines | 1 | 2001 | 36 | 0.040 |
Why?
|
| Benzeneacetamides | 1 | 2001 | 3 | 0.040 |
Why?
|
| Somatostatin | 1 | 2001 | 11 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 16 | 0.040 |
Why?
|
| Naltrexone | 1 | 2001 | 23 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 823 | 0.040 |
Why?
|
| Indiana | 1 | 2020 | 27 | 0.040 |
Why?
|
| Peptides | 1 | 2001 | 143 | 0.040 |
Why?
|
| Skin Temperature | 1 | 2000 | 17 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1262 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1999 | 35 | 0.040 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 1999 | 6 | 0.040 |
Why?
|
| Norepinephrine | 1 | 1999 | 103 | 0.040 |
Why?
|
| Child | 2 | 2020 | 2614 | 0.040 |
Why?
|
| Rest | 1 | 2019 | 53 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2013 | 1910 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2019 | 116 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 808 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2019 | 208 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2001 | 430 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 585 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2020 | 163 | 0.030 |
Why?
|
| Nerve Net | 1 | 2019 | 141 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 76 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 159 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 4 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 2463 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 203 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 87 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 31 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 257 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 176 | 0.030 |
Why?
|
| Sports | 1 | 2015 | 43 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 326 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1607 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 188 | 0.020 |
Why?
|
| Self Concept | 1 | 2013 | 47 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 2367 | 0.020 |
Why?
|
| African Americans | 1 | 2019 | 1435 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 75 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 267 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 16 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 74 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 922 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 140 | 0.020 |
Why?
|
| Injections, Epidural | 1 | 2009 | 9 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2009 | 13 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2007 | 3 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2007 | 35 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2007 | 111 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2007 | 47 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 81 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 397 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 597 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2004 | 21 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 45 | 0.010 |
Why?
|
| Pneumonia | 1 | 2004 | 70 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 480 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2004 | 65 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 125 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 703 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 1606 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 3 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Receptors, CCR4 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Bradykinin | 1 | 2001 | 12 | 0.010 |
Why?
|
| Substance P | 1 | 2001 | 23 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 11 | 0.010 |
Why?
|
| Capsaicin | 1 | 2001 | 32 | 0.010 |
Why?
|
| Tail | 1 | 2001 | 5 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2001 | 75 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 55 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2001 | 34 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 89 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 2001 | 70 | 0.010 |
Why?
|
| Yohimbine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Dexmedetomidine | 1 | 1999 | 12 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 545 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 46 | 0.010 |
Why?
|
| Anesthesia, Spinal | 1 | 1999 | 27 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 889 | 0.010 |
Why?
|